logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Alexandra Thomas

University of California System
H指数:27
被引数:2,821

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer

ASTX727联合talazoparib治疗三阴性或激素抵抗/HER2阴性转移性乳腺癌的Ⅰ期研究

Cancer
IF5.1
2026-04-140
OAAI
Kathy D. Miller MD; Alexandra Thomas MD; Sandra Althouse MS; Yong Zang PhD; Erin Conder MS, CCRP; Ryan Burgos BS, MBA; Bryan P. Schneider MD; Tarah Ballinger MD; Emily Douglas MD; Katherine Ansley MD; H. Josh Jang PhD; Woonbok Chung PhD; Jean-Pierre Issa PhD; Kenneth P. Nephew PhD; Feyruz V. Rassool PhD
RETRACTED: Thomas et al. Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers 2020, 12, 2279

撤回：Thomas等人。靶向递送艾霉素纳米载体可诱导化疗耐药性胰腺癌体内自噬介导的死亡。Cancers 2020, 12, 2279

Cancers 2025, Vol. 17, Page 3888
IF4.4
2025-12-050
OAAI
Alexandra Thomas; Abhilash Samykutty; Jorge G. Gomez-Gutierrez; Wenyuan Yin; Michael E. Egger; Molly McNally; Phillip Chuong; William M. MacCuaig; Sabrin Albeituni; Matthew Zeiderman; Min Li; Barish H. Edil; William E. Grizzle; Kelly M. McMasters; Lacey R. McNally
ASO Visual Abstract: Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

ASO可视化摘要：新辅助化疗与改善转移性乳腺癌的总体生存率无关，无论肿瘤亚型如何。

Annals of Surgical Oncology
IF3.5
2025-08-260
PRE
Ellery H. Reason; Samantha M. Thomas; Tori Chanenchuk; Astrid Botty van den Bruele; Maggie L. DiNome; E. Shelley Hwang; Kendra Modell Parrish; Ton Wang; Jennifer K. Plichta; Alexandra Thomas; Akiko Chiba; Laura H. Rosenberger
Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

新辅助化疗与肿瘤亚型无关，对化生性乳腺癌的总生存期无改善作用。

Annals of Surgical Oncology
IF3.5
2025-07-290
PRE
Ellery H. Reason; Samantha M. Thomas; Tori Chanenchuk; Astrid M. Botty van den Bruele; Maggie L. DiNome; E. Shelley Hwang; Kendra Modell Parrish; Ton Wang; Jennifer K. Plichta; Alexandra Thomas; Akiko Chiba; Laura H. Rosenberger
Pathologic complete response (pCR) rates for patients with HRD/HER2L high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在I-SPY2临床试验中，根据临床和分子特征，HRD/HER2L高风险早期乳腺癌（EBC）患者的病理完全缓解（pCR）率。

ANNALS OF ONCOLOGY
IF65.4
2025-02-012
PRE
Huppert, L. A.; Wolf, D.; Yau, C.; Brown-Swigart, L.; Hirst, G. L.; Isaacs, C.; Pusztai, L.; Pohlmann, P. R.; Demichele, A.; Shatsky, R.; Yee, D.; Thomas, A.; Nanda, R.; Perlmutter, J.; Heditsian, D.; Hylton, N.; Symmans, F.; van't Veer, L. J.; Esserman, L.; Rugo, H. S.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

NATURE MEDICINE
IF50
2024-09-141
PRE
Khoury, Katia; Meisel, Jane L.; Yau, Christina; Rugo, Hope S.; Nanda, Rita; Davidian, Marie; Tsiatis, Butch; Chien, A. Jo; Wallace, Anne M.; Arora, Mili; Rozenblit, Mariya; Hershman, Dawn L.; Zimmer, Alexandra; Clark, Amy S.; Beckwith, Heather; Elias, Anthony D.; Stringer-Reasor, Erica; Boughey, Judy C.; Nangia, Chaitali; Vaklavas, Christos; Omene, Coral; Albain, Kathy S.; Kalinsky, Kevin M.; Isaacs, Claudine; Tseng, Jennifer; Torres, Evanthia T. Roussos; Thomas, Brittani; Thomas, Alexandra; Sanford, Amy; Balassanian, Ronald; Ewing, Cheryl; Yeung, Kay; Sauder, Candice; Sanft, Tara; Pusztai, Lajos; Trivedi, Meghna S.; Outhaythip, Ashton; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Beedle, Carolyn; Perlmutter, Jane; Pohlmann, Paula; Shatsky, Rebecca A.; Demichele, Angela; Yee, Douglas; van't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

NATURE MEDICINE
IF50
2024-09-144
PRE
Shatsky, Rebecca A.; Trivedi, Meghna S.; Yau, Christina; Nanda, Rita; Rugo, Hope S.; Davidian, Marie; Tsiatis, Butch; Wallace, Anne M.; Chien, A. Jo; Stringer-Reasor, Erica; Boughey, Judy C.; Omene, Coral; Rozenblit, Mariya; Kalinsky, Kevin; Elias, Anthony D.; Vaklavas, Christos; Beckwith, Heather; Williams, Nicole; Arora, Mili; Nangia, Chaitali; Torres, Evanthia T. Roussos; Thomas, Brittani; Albain, Kathy S.; Clark, Amy S.; Falkson, Carla; Hershman, Dawn L.; Isaacs, Claudine; Thomas, Alexandra; Tseng, Jennifer; Sanford, Amy; Yeung, Kay; Boles, Sarah; Chen, Yunni Yi; Huppert, Laura; Jahan, Nusrat; Parker, Catherine; Giridhar, Karthik; Howard, Frederick M.; Blackwood, M. Michele; Sanft, Tara; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Heditsian, Diane; Lestage, Barbara; Perlmutter, Jane; Pohlmann, Paula; Demichele, Angela; Yee, Douglas; van 't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.

研究方向

暂未获取到该数据
A
Akiko Chiba
H 指数:21论文数:161被引数:1,523
A
Abhilash Samykutty
H 指数:18论文数:46被引数:2,219
L
Lacey R. McNally
H 指数:32论文数:204被引数:2,773
M
Molly McNally
H 指数:9论文数:28被引数:451
A
Angela DeMichele
H 指数:89论文数:736被引数:2.8万
D
Douglas Yee
H 指数:83论文数:583被引数:2.5万
C
Christina Yau
H 指数:92论文数:571被引数:7.9万
C
Claudine Isaacs
H 指数:97论文数:751被引数:3.7万
P
Paul A. Romitti
H 指数:60论文数:379被引数:1.2万
R
Rita Nanda
H 指数:56论文数:548被引数:1.6万